Warsaw, 17 October 2016
Warsaw, 17 October 2016
Celon Pharma S.A's Warsaw Stock Exchange IPOCelon Pharma S.A.'s IPO was held on the main market of the Warsaw Stock Exchange on 17 October 2016. The share price on the first day of trading increased by 17.58 percent. 15,000,000 of B series ordinary shares were introduced into the regulated market of the Warsaw Stock Exchange on the basis of a prospectus approved by the Polish Financial Supervision Authority (KNF).
Mercurius Dom Maklerski Sp. z o.o. was the Offerer in the process.
Maciej Wieczorek, CEO of Celon Pharma S.A.: Today I wish to thank the investors for the trust they gave to our Company and ensure them that I will be fully committed not to let them down.
Celon Pharma S.A. is a pharmaceutical company with an established position, growing revenues and a very clear vision of the future which implies both a dynamic international expansion of our flagship product and our constant presence in the race to conquer global pharmaceutical markets. This is also a vision which will help us effectively develop several innovative projects and commercialise them effectively in the next few years – adds Maciej Wieczorek.
Celon Pharma S.A. is the first biopharmaceutical company which at the same time specialises in developing, manufacturing and marketing of specialised generic drugs, as well as conducting research on innovative therapies to be listed on the Warsaw Stock Exchange. The Company's current product portfolio can be divided into standard generic drugs, combination generic drugs, and designs of new drugs, including potential innovative drugs. Celon Pharma S.A. has two fully equipped laboratories dedicated to research and development of medicinal products (R&D) for both generic and innovative drugs. It also has a modern manufacturing facility in Kazuń Nowy where dry pharmaceutical forms are manufactured.
ABOUT THE COMPANY
Celon Pharma S.A. is an integrated pharmaceutical company which conducts advanced research and manufactures modern drugs. It was founded in 2002 by Maciej Wieczorek, PHD. Celon Pharma S.A. has two fully equipped laboratories dedicated to research and development of medicinal products (R&D) for both generic and innovative drugs. Two of Celon Pharma S.A.'s production plants have appropriate GMP (Good Manufacturing Practice) authorisations. The main office and the laboratories are located within 30 km from the centre of Warsaw. The company currently has approx. 250 employees. It employs 62 scientists responsible for research and development, half of whom either have a PhD or are in the process of acquiring their PhD.
Further information can be obtained from:
Piotr Sitarek728518033
Małgorzata Siewierska
602 301 215